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For a long time, natural killer (NK) cells were thought to be the only innate immune lymphoid
population capable of responding to invading pathogens under the influence of changing
environmental cues. In the last few years, an increasing amount of evidence has shown
that a number of different innate lymphoid cell (ILC) populations found at mucosal sites
rapidly respond to locally produced cytokines in order to establish or maintain homeostasis.
These ILC populations closely mirror the phenotype of adaptive T helper subsets in their
repertoire of secreted soluble factors. Early in the immune response, ILCs are responsi-
ble for setting the stage to mount an adaptive T cell response that is appropriate for the
incoming insult. Here, we review the diversity of ILC subsets and discuss similarities and
differences between ILCs and NK cells in function and key transcriptional factors required
for their development.
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INTRODUCTION
The adaptive immune system has evolved antigen receptor diver-
sity to cope with a large variety of pathogens and non-self antigens.
It is well-established that, depending on the nature of the invader
and the signals coming from the surrounding environment, the
adaptive immune system mounts a specific effector T helper (Th)
response that serves to control the trespasser and re-establish
homeostasis. Functionally, Th1 eliminate intracellular pathogens,
Th2 are critical in promoting the eradication of helminthes, and
Th17 control fungal and bacterial infections (1).
In the last few years, it has become evident that the innate
immune system displays a similar strategy in order to ensure a first
line of defense against intruders via innate lymphoid cells (ILCs).
Broadly, ILCs are defined by their lymphoid lineage and their lack
of RAG-mediated recombined antigen receptors. Mirroring the
Th subsets, ILC populations diverge from one another in their
reliance on unique transcription factors and production of signa-
ture cytokines. In general, ILCs provide primary border patrol at
mucosal surfaces sensing changes in the microenvironment and
rapidly responding to insults by producing specific cytokines that
limit the damage caused by the attacking pathogen or favor its
clearance and elimination.
Until ILCs came into the spotlight, conventional NK cells
(cNKs) (i.e., blood circulating CD56+ cells in human and splenic,
lymph node, and bone marrow NKp46+NK1.1+ cells in mouse)
were the only innate immune cells known to respond to cytokines
produced by antigen presenting cells (APCs), such as dendritic
cells (DCs) and macrophages (2–4).
Natural killer (NK) cells can rapidly release IFN-γ in response
to IL-12 and IL-18 and/or type 1 IFN, which are produced when
viruses and bacteria infect or come into contact with APCs.
Because of their capacity to immediately respond to cytokines,
cNK cells can be viewed as the prototype of all ILC subsets.
However, they have additional properties, such as cytotoxic ability,
that set them apart from other ILCs and allow them to eliminate
virally infected or tumor-transformed cells.
Here, we will review the lineage relationship between ILC sub-
sets and cNKs based on key transcription factors that regulate their
respective development as well as the current understanding their
functional roles.
ILC HETEROGENEITY AND FUNCTIONAL SPECIALIZATION
Innate lymphoid cells, like Th cells, are heterogeneous and cur-
rently grouped in three major subsets: ILC1, ILC2, and ILC3 (5).
GROUP 1 ILCs
ILC1s produce the Th1 signature cytokine IFN-γ. They include
cNK [reviewed in detail in Ref. (6, 7)] and several addi-
tional, recently described, subsets of IFN-γ-producing cells (8–10)
(Table 1).
A brief overview of cNK cells
Conventional NK cells have been known and actively studied
for almost four decades (11, 12). cNKs were first described as
a cell subset capable of rapidly eliminating tumor-transformed
or allogeneic cells without the need for prior sensitization and
in the absence of RAG-recombined antigen receptor recogni-
tion (13, 14). Traditionally, cNK cells are thought to be criti-
cal in conferring protection from viral infections, such as CMV
(15), and in the immunosurveillance of tumor-transformed
cells (16, 17).
In humans, cNKs include the CD56brightCD16− and the
CD56dimCD16+ subsets present in peripheral blood. CD56bright
NK cells are specialized in IFN-γ secretion in response to
DCs/macrophages-derived cytokines, such as IL-12 and IL-18 (18)
or T cell-derived cytokines, such as IL-2 (19), a functional feature
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Table 1 | Emerging subsets of ILC1 and tissue-resident NKs.
CD127 IL-15
dependence
IL-7
dependence
TBX21
dependence
Eomes
dependence
E4BP4
dependence
Human counterpart
siLP ILC1 +++ Yes No Yes No Partial Most likely
CD127+CD56−CD94−
mucosal cells
Intraepithelial ILC1 − Partial No Yes TBD Yes CD56+NKp44+
CD103+CD160+ cells in
human tonsil and intestine
“Converted” or
“plastic” ILC3
+++ No, but IL-15 can
promote
conversion
Yes Yes No TBD Mostly generated in vitro
cNKs (splenic, bone
marrow, lymph nodes)
− Yes No Yes Yes Yes Most likely CD56dimCD16+
blood NKs
Thymic NK cells +++ Yes Yes Yes Yes Yes Most likely CD56brightCD16−
blood NKs
Liver-resident
CD49a+DX5− NKs/ILC1
− Yes TBD Yes No No TBD
Skin-resident
CD49a+DX5− NKs
− Yes TBD Yes TBD No TBD
Uterus-resident
CD49a+DX5− NKs
− Yes TBD No TBD No TBD
Salivary gland NKs − Yes TBD TBD TBD No TBD
TBD, to be determined.
that place them close to other ILC1 subsets. CD56dimCD16+ NKs
are specialized in cytotoxicity, since they can readily release lytic
granules containing perforin and granzyme upon contact with
sensitive targets. However, it has been shown that also CD56dim
NK cells can produce IFN-γ, although with a more rapid kinetic
and in a less sustained fashion than CD56bright NKs (20). In
addition, it has been suggested that CD56bright can differentiate
into CD56dim NKs upon activation (21, 22). CD56bright cells pro-
duce additional monokines such as GM-CSF, TNF-α, IL-13, and
IL-10, suggesting that they may exert an immunoregulatory func-
tion in specific circumstances (23). In addition, CD56bright NKs
express CCR7, CXCR3, and CD62L and they are thought to traf-
fic to secondary lymphoid organs via high endothelial venules
(HEVs) (24).
In mouse, cNK include mature (CD11bhighCD27low) and
immature (CD27highCD11blow) circulating splenic and bone mar-
row NKs (25), CD127+ (the IL-7 receptorα chain) IL-7-dependent
thymic-derived NKs (26), and different subsets of tissue-resident
NKs (12, 27) whose nature, function, and relationship to other
emerging subsets of ILC1 we are just beginning to understand.
Tissue NKs include an abundant population of salivary gland
NKs, which are poorly cytotoxic and poor producers of cytokines
(28, 29), liver-resident CD49a+ (VLA1) DX5− NK cells, and skin-
and uterus-resident NK cells (30). Thymic NKs for their ability
to produce IFN-γ, TNF-α, and GM-CSF in response to IL-12 are
thought to represent the murine counterpart of human CD56bright
NK cells. One unifying feature of all NK cell subsets, including
thymic NKs (31), is their dependence on IL-15 and IL-15Rα for
development, survival, and maintenance.
The major breakthrough in understanding the biology and
function of cNK cells was the discovery of germ line-encoded
cell surface receptors of the C-type lectin or of the immunoglob-
ulin superfamily that deliver either inhibitory or activating signal
to NK cells (3, 32–35). These receptors, some of which are clon-
ally distributed, finely tune NK cytolytic ability and the capacity
to release cytokines through recognition of MHC class I mole-
cules or other counter-receptors specifically expressed by target
cells upon infection, tumor transformation, or stress-related sig-
nals (36). The appreciation of the complex array of signaling
receptors expressed by cNKs has challenged the idea that NK cells
simply exert “natural” cytotoxicity, and has suggested that in addi-
tion to “missing self” (37), which leads to release of inhibition
mediated by inhibitory receptors that recognize self MHC class
I, NK cells have to integrate a complex network of clues, which
depend on contact with the target cells and/or the surrounding
microenvironment. Accordingly, recent work has suggested that
engagement of cytokine receptors can influence NK cell recog-
nition mediated by activating receptors, such as NKG2D (38).
Importantly, expression of inhibitory and activating receptors on
NK cells controls their education and “licensing” (39), as well as
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their expansion during responses to pathogens. This expansion
generates a long lived-memory-type NK cell progeny that is more
effective in clearing infections upon a second challenge (6, 40).
Thus cNK cells possess some features adaptive immune cells
that maximize their capacity to eliminate intruders while avoiding
self-reactivity (7).
Emerging ILC1 subsets
One first subset of ILC1 is present in human mucosal tissues
and expresses CD127 and the C-type lectin CD161, but does not
express other markers of the NK lineage such as CD94, CD56,
NKp44 (NCR2), or NKp46 (NCR1); although it rapidly responds
to IL-12 and IL-18 by producing IFN-γ (8). These cells also do not
express c-kit (the receptor for stem cell factor, SCF), which marks
many other ILC subsets.
The second subset was identified in human tonsillar tissue and
is characterized by the expression of several NK-related mark-
ers such as CD56, NKp46, and NKp44 (9). However, this subset
also expresses markers of tissue-resident memory CD8 T cells
such as CD103, CD49a, and CD101. These ILC1s are also present
in mouse small intestine, have an intraepithelial location, and
are distinguished by the expression of CD160, a receptor of the
immunoglobulin superfamily that binds to the TNF receptor
superfamily member HVEM. HVEM–CD160 interactions pro-
mote epithelial integrity by inducing the alternative NF-kB sig-
naling pathway and Stat3 phosphorylation in epithelial cells (41).
Intraepithelial resident ILC1s are distinguished by cNKs because
they do not respond to IL-12 and IL-18. Alternatively, they secrete
large amounts of IFN-γ upon stimulation with IL-15. Notably,
intraepithelial ILC1s are only partially dependent on IL-15/IL-
15Rα signaling for their development, a feature that set them
apart from cNKs. Interestingly, these ILC1s seem to promote
tissue damage in a mouse model of colitis induced by CD40 lig-
ation in immune-deficient mice. Although the function of the
newly described human ILC1 subsets has not been investigated in
detail in vivo, they may play important pathogenic roles in human
inflammatory bowel diseases (IBDs) as both CD56−CD127+ and
NKp44+CD103+ ILC1s are increased in patients with Crohn’s dis-
ease, as compared to control individuals (8, 9). For instance, earlier
studies have suggested that IL-15 and retinoic acid are highly path-
ogenic factors in celiac disease, since they induce production of
IL-12 by intestinal DCs (42). In light of the fact that one ILC1
subset is responsive to IL-12, while the other promptly reacts to
IL-15, it would be interesting to explore the respective role of
these ILC1 subsets in human celiac disease or mouse models of
celiac disease.
A putative murine equivalent of the CD56−CD127+ human
ILC1s has been recently described in small intestine lamina propria
(siLP) (10). These cells are CD127+, but also express markers of the
NK lineage, such as NKp46 and NK1.1. Interestingly, siLP ILC1s, as
cNKs, depend on IL-15, but not IL-7, for their development. In vivo
these cells are major producers of IFN-γ and TNF-α in response
to oral infection with Toxoplasma gondii (T. gondii) and promote
clearance of this pathogen by recruiting inflammatory monocytes
through the CCR1/CCL3 axis (43). Therefore, in these settings,
siLP ILC1s play a major protective role. Most likely, clearance of
T. gondii requires a strong Th1 environment, while in Crohn’s
disease a robust Th1 signature sustains autoimmune damage and
tissue destruction, explaining why ILC1s may play protective or
pathogenic roles in different scenarios and in different diseases.
Another subset of ILC1s is represented by the so-called “con-
verted” or “plastic” ILC3s. These cells can be generated in vitro
from ILC3s in response to cytokines such as IL-15, IL-2, IL-12,
and IL-23 that induce IFN-γ production (8, 44). They can also be
induced in vivo by transfer of RORγt+ ILC3s and visualized by
fate-mapping experiments in siLP (10, 45, 46).
GROUP 2 ILCs
ILC2s produce the Th2 signature cytokines IL-5 and IL-13 (47–50).
They also produce amphiregulin and IL-9, and notably, IL-9/IL-
9 receptor signaling is required for their survival (51). ILC2s are
found in various tissues including adipose tissue-associated lym-
phoid structures, gut, lung (52) and, as recently described, the
skin (53–55). They promote expulsion of parasites (56, 57) and
maintain lung homeostasis (58) or drive airway hyper-reactivity
during viral infections, such as influenza (59). They also contribute
to the pathogenesis of atopic dermatitis (53–55). In visceral adi-
pose tissue, ILC2s maintain metabolic homeostasis by recruiting
eosinophils, which sustain macrophage alternative activation (60,
61). ILC2s rapidly respond to the alarmin IL-33, to the IL-17 fam-
ily member IL-25 and to TSLP in skin (62). They are characterized
by the expression of CD127, c-kit, Sca1, and ST2 (the receptor
for IL-33). Human ILC2s express CD161 and high levels of the
prostaglandin D2 receptor CRTH2 (63). Notably, ILC2s are highly
enriched in nasal polyps of patients with chronic rhinosinusitis
(63), suggesting that they might play a fundamental role in human
Th2-mediated diseases such as asthma and atopic dermatitis. A
subset of cells named multipotent progenitor type 2 (MPPtype2),
originally classified within ILC2s because of their ability to expand
in response to IL-25, have been recently shown to contain prog-
enitors giving rise to myeloid cells, such as macrophages and
eosinophils (50). Because of the distinct transcriptional profile
and functional potential that distinguishes MPPtype2 from other
ILC2s, and ILCs in general, these cells are no longer classified as
Group 2 ILCs.
GROUP 3 ILCs
ILC3s produce the Th17 signature cytokines IL-17 and/or IL-22
(64–69). ILC3s include Lineage− (Lin)RORγt+ CD4+ Lti-like cells
originally described in the 1990s (70), Lin− RORγt+ CD4− Lti-
like cells, NCR+ ILC3s originally named NK-22 (65), and colonic
Sca1+ Thy1high ILCs (71). ILC3s rapidly respond to IL-23, a mem-
ber of the IL-12 family. They also express the IL-1 receptor and
respond to IL-1β (44, 72). ILC3s are mainly found in mucosal tis-
sues, such as small and large intestine, Peyer’s patches (PP), and
gut-associated lymphoid tissue (GALT). Small numbers of ILC3s
are present in spleen (73) and lung (74). By producing IL-22,
ILC3s protect intestinal epithelium in vivo from attaching and
effacing bacteria, such as Citrobacter rodentium, a mouse model
of human enteropathogenic E. coli (75). IL-22 acts selectively on
stromal and epithelial cells by inducing STAT3 phosphorylation,
leading to multiple downstream events including the rapid pro-
duction of the antimicrobial peptides alpha and beta defensins, as
well as the promotion of epithelial cell survival and proliferation
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(75, 76). ILC3s and ILC3-derived IL-22 are critical in contain-
ing dissemination of commensal bacteria in immune-deficient
animals. In the absence of ILC3s, host-derived bacteria of the
Alcaligenes species disseminate to peripheral organs and induce
systemic inflammation (77). IL-22 also acts on intestinal epithe-
lial stem cells, and radio-resistant IL-22-producing ILC3s from the
recipient are key to limit the severity of intestinal damage during
graft versus host disease (GVHD) (78).
While in the short term IL-22-mediated survival and prolif-
eration of epithelial cells may favor tissue healing and repair,
prolonged IL-22 signaling, and sustained epithelial proliferation
may drive tumor formation (79). Accordingly, recent evidence
has linked colonic ILC3s to colon cancer in a genetically prone
bacterial-driven model of colon cancer (80). ILC3s have also been
involved in other human disease, such as Crohn’s disease (81) and
psoriasis (82).
NCR− ILC3s have been shown to negatively regulate adaptive
CD4 T cell responses to commensals. This process does not depend
on IL-17 or IL-22 but requires MHC class II expression on ILC3s
and, by mechanisms yet to be completely elucidated, restricts CD4
T cell proliferation to commensal antigens (83).
Interestingly, in human tonsil, ILC3s produce GM-CSF, BAFF,
and LIF in addition to IL-22 and express high levels of CD40L and
RANKL (44). GM-CSF promotes accumulation of granulocyte-
monocyte progenitors (GMPs) and mediates immunopathology
in a mouse model of T cell-mediated colitis (84). Surprisingly,
in steady state conditions, ILC3-derived GM-CSF is essential to
induce development of CD103+CD11b+ DCs that instruct differ-
entiation of FoxP3+ Treg cells in an IL-10, TGF-β, and retinoic
acid-dependent fashion. ILC3s produce GM-CSF selectively upon
stimulation with IL-1β, which is released by macrophages acti-
vated by microbial products (85). Selective loss of GM-CSF in
ILC3s results in impaired oral tolerance to dietary antigens.
CD40L expression and BAFF production by ILC3s enhance
antibody secretion by marginal zone B (MZB) cells (86). Interest-
ingly, ILC3s activate marginal reticular cells (MRCs) by providing
TNF-α and lymphotoxin (LT). They also receive survival signals
from MRCs, including IL-7. The interaction between MZB cells
and ILC3s also involves expression of DLL1 by ILC3s, a Notch lig-
and that may activate Notch2 on MZB cells (86). Furthermore, in
these settings, GM-CSF produced by ILC3s promotes APRIL secre-
tion by neutrophils, boosting their B helper phenotype and further
promoting IgM, IgG, and IgA production by MZB cells. RORγt+
LTi-like ILC3s induce T cell-independent IgA production in iso-
lated lymphoid follicles (ILFs). The simultaneous stimulation of
stromal cells by LTi-like cells, via LT/LTβR, and by bacteria, via
TLRs, induces recruitment of DCs and B cells promoting forma-
tion of ILFs and boosting T cell-independent IgA production in
ILFs (87). Type 3 ILCs have also been shown to control T cell-
dependent IgA production through release of soluble LTα3, which
induces T cell homing to the gut (88). Ultimately, reduction in
IgA levels due to absence or dysfunction of ILC3s in small intes-
tine will induce changes in the microbial communities that may
cause immunopathology. Collectively, these studies indicate that
ILC3s may provide help to B cell responses at mucosal barriers
by multiple mechanisms that may cooperate in providing optimal
protection from environmental insults.
The relevance of LIF production and RANKL expression by
ILC3s has yet to be understood. However, RANKL has been shown
to be essential for the differentiation of the specialized microfold
cells (M cells) that overlay the dome region of PP (89). Therefore,
RANKL expression by ILC3s could be relevant in the context of PP
function and biology and in the transport of particulate antigen
from the lumen to APCs located in the sub-epithelial dome area
of PP.
Although a transient burst of IL-22 from ILC3s seems to play
protective effects in many scenarios and in particular during bac-
terial infections, a recent study has defied this view. IL-22 induces
robust expression of antimicrobial proteins, such as lipocalin and
calprotectin. These proteins are known to sequester metal ions
including iron, zinc, and manganese. By subtracting these ions to
commensal bacteria, IL-22 favors expansion of pathogenic bac-
teria, such as Salmonella typhimurium that are resistant to ion
starvation (90). Therefore, in some circumstances, ILC3s may tip
the balance in favor of pathogens, rather than protect from their
attack.
In addition to sensing cytokines released in the surrounding
microenvironment, ILC3s are also sensitive to nutrients. Recent
work has shown that vitamin A deficiency results in decreased
numbers of ILC3s in the intestine, which increases susceptibil-
ity to bacterial infections. However, the same deficiency induces
expansion of ILC2s, which protect from nematode infections (91).
Moreover, vitamin A intake by pregnant mothers controls the pool
of LTi-like CD4+ ILC3s in embryos, the size of lymph nodes and
PP, and the efficacy of immune responses to viral infections (92).
These findings again emphasize the idea that ILCs are exquisitely
sensitive to environmental cues and continuously adapt to rapidly
changing settings, such as the ones present at mucosal surfaces.
THE NETWORK OF MASTER REGULATORS OF ILC
DEVELOPMENT
Until recently, the general consensus was that the very same tran-
scription factors that drive Th1, Th2, and Th17 commitment and
differentiation also regulate ILC1, ILC2, and ILC3 development,
respectively. Moreover, it seemed that cNKs and the other ILC
groups significantly differed in their developmental requirement
for transcription factors.
This concept has been recently challenged by a number of stud-
ies suggesting that developmental requirements for NK cell subsets
and ILCs are more complex than originally anticipated (Figure 1).
Here, we will highlight the most recent progresses in the field.
All ILC groups, including cNKs, depend on Id2 (47, 93). Id2
is a transcriptional repressor that, by blocking members of the E2
family of transcription factors, suppresses the B cell fate poten-
tial in a progenitor cells that develop downstream of the common
lymphoid precursor (CLP). A recent study that took advantage
of a reporter mouse expressing GFP under the control of the
Id2 promoter to track Id2-expressing cells has shown that Id2 is
not expressed in CLPs. Id2 is, however, expressed at very high
level in all ILCs, including cNKs (94). In NK cells, Id2 is not
required for the NK cell lineage specification, since development
of CD122+NK1.1− NK cell progenitors is not impaired in Id2-
deficient mice. Nevertheless, Id2 expression in NK cells is required
for acquisition of a fully mature phenotype. The few NK cells that
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FIGURE 1 |The major transcriptional pathways that control ILC and
NK cell development. Indicated in red are the key transcription factors
that have been shown being absolutely required in vivo for the
development of each cell subset. “Emergency” NK cells are NK cells that
develop in the absence of E4BP4, following viral infection. It is presently
unclear whether these cells are Tbet-dependent. CHILP, common helper
innate lymphoid precursor; CLP, common lymphoid progenitor;
cILC2/ILC3p, common ILC2/ILC3 progenitor.
develop in the absence of Id2 have a phenotype that closely resem-
ble thymic NK cells, express high levels of CD127 and produce
large amounts of IFN-γ (95). In committed B cells, the tran-
scription factor EBF1 mediates Id2 suppression (96). According
to the idea that Id2 is globally required for development of all
ILCs, EBF1-deficient pro-B cells acquire the capacity to differ-
entiate into T cells and into functionally competent ILC2s and
ILC3s (97). Importantly, the generation of an Id2-reporter mouse
has allowed the identification of a common ILC progenitor, or
CHILP (common “helper-like” ILC lineages progenitor) (10) that
can generate CD127+NKp46+ siLP ILC1, ILC2, and ILC3 in vivo
and in vitro. This Lin−Id2+ progenitor also expresses CD127 and
the integrin α4β7 but does not express CD25 (which is present on
differentiated ILC2) or CD122, a marker of NK cell precursors.
Intriguingly, this precursor is only slightly affected by IL-7 defi-
ciency and can generate liver-resident CD49a+Eomes− NK cells,
but not cNKs (10). Further confirming the existence of a common
ILC progenitor, an other recent study performing fate-mapping
experiments shows that ILCs, including intraepithelial ILC1, ILC2,
and NCR+ ILC3, derive from a common committed precursor
present in fetal liver and adult bone marrow that transiently
expresses the transcription factor PLZF (encoded by Zbtb16) (98).
This transcription factor was known to be required for NKT devel-
opment, but it is dispensable for cNK cells and CD4+ LTi-like
cells (99). Reconstitution experiments with Zbtb16-deficient or -
sufficient bone marrow cells in lethally irradiated mice indicated
that Zbtb16 is absolutely required for ILC2s development only. On
the contrary, it seems to be dispensable for NCR+ ILC3s recon-
stitution, despite its high expression in this subset. As Zbtb16 is
controlled by Id2 (100), the PLZF-expressing common ILC pre-
cursor may be downstream of the Id2+CD127+CD25−α4β7+
CHILP.
Most likely downstream of the CHILP, all ILC3 subsets require
the Th17 master regulator RORγt (101, 102). In the absence
of RORγt, Lti, and Lti-like cells fail to develop and RORγt-
deficient mice do not possess lymph nodes, PP, cryptopaches
(CP) nor ILFs (103, 104), which derive from CP under sig-
nals coming from the microbiota through the nod-like receptor
(NLR) NOD1 (105). ILC3s also require aryl hydrocarbon recep-
tor (AHR) (106–108), which drives IL-22 secretion in Th17 cells
(109, 110). In the absence of AHR, both Lti-like ILC3s and NCR+
ILC3s are severely diminished. In addition, small intestine CP
and ILFs are absent, while colonic patches develop normally
(111). Some studies have suggested that exogenously provided
AHR agonists, such as tryptophan derivatives added to the diet,
play a role in expanding and/or maintaining ILC3s (106, 112).
Recent work has also shown that AHR agonists derived from
commensal bacteria, such as lactobacilli, increase IL-22 produc-
tion by ILC3s in the context of a tryptophan rich diet and this,
in turn, confers resistance to infection by the opportunistic fun-
gus Candida albicans (113). It is also possible that endogenous
AHR ligands, such as kynurenine, produced by the enzyme tryp-
tophan dioxygenase (TDO), may play a critical role in ILC3
biology (114).
Unexpectedly, AHR, in ILC3 cells, restrains adaptive Th17
responses. In AHR-deficient mice that lack ILC3s, Th17 cells in
siLP undergo an uncontrolled expansion that leads to tissue dam-
age. This Th17 proliferation is due to a dysregulation in the
intestinal microbial niche that allows excessive growth of seg-
mented filamentous bacteria (SFB), commensals known to drive
Th17 differentiation (115).
In addition to RORγt and AHR, ILC3s also depend on Notch
signaling for their development (111, 116). In RBP-Jk
−/− mice
that lack all Notch signaling, NCR+ ILC3s are selectively reduced.
Notch also promotes RORγt+ ILC differentiation from adult bone
marrow precursors (117). Recent studies have also shown that
NCR+ ILC3s, which develop post-natally and reach maximal
expansion 4–6 weeks after birth in mouse small intestine LP (118),
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express Tbet (encoded by Tbx21) and require Tbet for develop-
ment (46, 116, 119, 120). Induced by IL-23 and cues from the
microbiota, Tbet is essential to instruct IFN-γ production and
protection from pathogens such as S. typhimurium (46). Tbet
expression seems to induce Notch, as Tbet haplo-insufficiency
results in reduced Notch expression (116). However, it is con-
ceivable that AHR and Tbet may cooperate in inducing Notch and
final maturation of NCR+ ILC3s.
The requirement for Tbet in NCR+ ILC3s is somewhat sur-
prising since human tonsil ILC3s do not express Tbet ex vivo
(44). In fact, in steady state conditions, Tbet expression is lim-
ited to ILC1s and cNKs, while RORγt is selectively expressed by
ILC3 (9).
Human tonsil ILC3s also express high levels of CCR6 and can
easily be sorted at high purity based on NKp44 and CCR6 expres-
sion (44, 121), while mouse NCR+ ILC3s are CCR6 negative (46).
Whether the discrepancies between the mouse and human system
are linked to tissue specific differences (intestine versus tonsil)
still remains to be determined. It is conceivable that Tbet may
be needed at later stages of ILC3s differentiation, which may be
poorly represented in the tonsil. In agreement with this hypoth-
esis, tonsil ILC3s are characterized by an intrinsic plasticity and,
when stimulated with cytokines such as IL-2 and IL-15 in vitro,
can generate IFN-γ producing pro-inflammatory cells that acquire
some features of cNK (8, 44). Specific engagement of cell sur-
face receptors expressed by ILC3s by cognate ligands present in
some tissues but not in others may also be an issue. Indeed,
a recent study has suggested that stimulation of ILC3s via the
DAP12-associated activating receptor NKp44 induces production
of TNF-α and convert them to a more inflammatory-prone cell
type (122). Experiments in mice have suggested that ILC3 conver-
sion to an IFN-γ/TNF-α secreting pro-inflammatory cell type can
occur in vivo (45). Moreover, recent fate-mapping experiments,
aimed to track cells that expressed RORγt at any stage of their life
cycle, show that “plastic” or “converted” ILC3s are present within
the RORγt−NKp46+NK1.1+ population in siLP and cluster with
siLP ILC1s and cNK (10).
Finally, STAT3 expression in ILC3s is required for robust IL-
22 production and protection by intestinal infection with C.
rodentium (123).
Group 2 ILCs necessitate RORα (124), Gfi1 (125), and Gata-3
for their development (94, 125–127). Gfi1 specifically controls the
response to IL-33 and TSLP and the production of IL-5, but not IL-
13, in ILC2s (125). The requirement for Gata-3 by ILC2s closely
resembles the need for Gata-3 in Th2 differentiation. However,
Gata-3 is also necessary for thymic NK cell development (26).
Moreover, a recent study has indicated that Gata-3 is required
for the generation of ILC3s (128), before the identification of the
CHILP (10). Transfer of Gata-3-deficient fetal liver precursor cells
in mice lacking ILCs prevents reconstitution of all RORγt+ ILC3s.
This finding has led to the hypothesis that a common precur-
sor might exist between ILC2s and ILC3s (128). In agreement
with this view, another transcription factor TCF-1 (encoded by
Tcf7) is required for ILC2s and NCR+ ILC3s (129, 130). TCF-
1 in ILC2s acts downstream of Notch and forced expression of
TCF-1 can bypass Notch requirement for ILC2 generation. TCF-
1 also induces Gata-3, which is responsible for upregulation of
Il-17rb (the receptor for IL-25) and Il2ra (CD25) in develop-
ing ILC2s. However, in the absence of Gata-3, TCF-1 directly
controls the expression of Il7r (CD127) (130). In NCR+ ILC3s,
TCF-1 acts downstream of Tbet and Notch to promote ILC3
development (129).
Gata-3 is also required to induce differentiation and/or main-
tenance of siLP ILC1s (10), as deletion of Gata-3 in NKp46+ cells
results in a dramatic reduction of this ILC subset, while does
not affect ILC3s or cNKs. In addition, early deletion of Gata-3
in hematopoietic cells abolishes the development of all CD127+
ILCs (131).
While it is not clear whether TCF-1 is also required for siLP
ILC1s, the data available suggest that some transcription factors
may be required at multiple stages of ILC differentiation and may
be turned on and off at different transitional steps with a hierarchy
that is still poorly defined.
Intraepithelial ILC1s and cNKs cells share some require-
ments in transcription factors for their differentiation. To begin,
both cell populations require Tbet for development (9, 132).
In addition, Tbet is necessary for the development of liver-
resident NK cells that express Trail, CD49a, lack DX5, and
Eomes (133) and have features of tissue-resident memory cells
based on parabiosis experiments (30, 134). Although these cells
were originally thought to represent an NK immature cell sub-
set (135), more recent data suggest that they represent a dis-
tinct lineage of NK cells that share part of their transcrip-
tional program with NKT cells (133). While it is not clear
whether intraepithelial ILC1s derive from the CHILP, liver-
resident NK cells could represent a true subset of ILC1s related
to the siLP ILC1s, since they appear to differentiate from the
CHILP (10).
Intraepithelial ILC1s and cNK cells also require E4BP4
(encoded by Nfil3) to develop (9, 136, 137). E4BP4 in NK cell
development was previously thought to act directly downstream
of IL-15R, which is required for NK cell maintenance (138, 139).
However, more recent data suggest that viral infections can res-
cue NK cell development independently of E4BP4 in a process
that requires inflammatory cytokines such as type 1 interferon
and IL-12 along with ITAM signaling (140). E4BP4-independent
NK cells are functional and persist in the periphery in an IL-
15 dependent fashion. Ablation of E4BP4 after the earlier steps
of NK cell commitment completely bypasses the requirement
for E4BP4 in NK cell development (140). In addition, E4BP4
is less stringently required for NK cell development outside of
the bone marrow. Liver-resident Trail+, DX5− NK cells develop
in the absence of E4BP4, especially when T cell competition is
eliminated (30, 141, 142). Salivary gland NKs also do not require
E4BP4 (29). The role for E4BP4 in thymic NK cell development
is still controversial. Thymic NK cells seem to develop normally
in vitro from E4BP4-deficient double negative (DN)1 and DN2
thymocytes (141). However, a second study indicates that thymic
NKs in vivo develop along an E4BP4-dependent pathway (142).
According to this report, E4BP4 is necessary to enforce Eomes
expression in cNKs as well as in thymic NKs. Further confirming
that E4BP4 may be necessary to drive Eomes expression, another
report demonstrates that E4BP4 is strictly required for the tran-
sition from CLP to NK cell progenitor and regulates Eomes and
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Id2 expression in NK cells (143). Challenging the previous con-
cept that E4BP4 acts downstream of the IL-15R (136), this study
shows that E4BP4 operates upstream of IL-15 signaling and in the
absence of E4BP4 CD122+ NK precursors fail to develop. E4BP4
expression is detected earlier that Tbet, Eomes, or Id2 expression
and chromatin immunoprecipitation experiments demonstrate
that E4BP4 promotes transcription of Eomes and Id2 by bind-
ing directly to the regulatory regions of their genes (143). These
data are, however, in conflict with the study by Seillet et al., which
shows that Id2 expression is normal in the absence of E4BP4 (142).
Further studies will be necessary to elucidate the exact hierarchy in
which transcription factors need to be expressed in order to grant
successful development and maturation of NK cells and ILCs.
Finally, cNK cells share with CD4+ LTi-like cells the require-
ment for the HGM-box transcription factor superfamily member
TOX. TOX-deficient animals lack NK cells and do not develop
lymph nodes nor PP (144). Although it has been hypothesized
that TOX controls induction or maintenance of Id2 in precursor
cells, the exact mechanisms by which TOX regulates development
of cNKs and LTi-like cells and whether it is necessary for other ILC
subsets is unclear.
CONCLUDING REMARKS
Studies over the past few years have indicated that adaptive immu-
nity has adopted modules already established in the innate branch
of the immune system to counteract pathogens and to maintain
homeostasis at mucosal surfaces, which are constantly exposed
to environmental insults and non-self-microbial communities.
The identification of innate subsets that mimic Th1, Th2, and
Th17/Th22 Thelper cells has greatly advanced our understanding
of how immune responses are orchestrated and shaped. Future
challenges in the field will be to understand whether additional
subsets of ILCs are present that prevent or control autoimmune
processes, i.e., whether an innate functional equivalent of regula-
tory T cells is in place. In addition, it will be important to delineate
whether dedicated subsets of APCs or stromal cells are located
in mucosal tissues that can preferentially activate a particular
ILC group, or whether this activation process depends on spe-
cific signals provided by the intruder. Elucidating whether diverse
inflammatory milieus can elicit different responses and immuno-
logical outcomes from the same ILC group will be also important.
In the long term, a better understanding of the very first events that
take place early on during the initiation of an immune response
may be key in designing better strategies for vaccine development
and therapeutic intervention.
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